BR9909660A - Caspase inhibitors - Google Patents

Caspase inhibitors

Info

Publication number
BR9909660A
BR9909660A BR9909660-9A BR9909660A BR9909660A BR 9909660 A BR9909660 A BR 9909660A BR 9909660 A BR9909660 A BR 9909660A BR 9909660 A BR9909660 A BR 9909660A
Authority
BR
Brazil
Prior art keywords
sym
compounds
diseases
relates
methods
Prior art date
Application number
BR9909660-9A
Other languages
Portuguese (pt)
Inventor
Marion W Wannamaker
Guy W Bemis
Paul S Charifson
David J Lauffer
Michael D Mullican
Mark A Murcko
Keith P Wilson
James W Janetka
Robert J Davies
Anne-Laure Grillot
Zhan Shi
Cornelia J Forster
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BR9909660A publication Critical patent/BR9909660A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE CASPASES"<D>. A presente invenção refere-se a novas classes de compostos que são inibidores de caspase, em particular inibidores de enzima de conversão de interleucina-1beta ("ICE"). Esta invenção também refere-se a composições farmacêuticas compreendendo estes compostos. Os compostos e as composições farmacêuticas desta invenção são particularmente bem adequados para a inibição de atividade de caspase e conseq³entemente, podem ser vantajosamente usados como agentes contra doenças mediadas por interleucina-1 ("IL-1"), apoptose, fator de indução de interferon-<sym> (IGIF), ou interferon-<sym> ("IFN-<sym>"), incluindo doenças inflamatórias, doenças auto-imunes, distúrbios de osso destrutivos, distúrbios proliferativos, doenças infecciosas, e doenças degenerativas. Esta invenção também refere-se a métodos para a inibição de atividade de caspase e diminuição de produção de IGIF e produção de IFN-<sym> e a métodos para o tratamento de doenças mediadas por interferon-<sym>, apoptose, e interleucina-1 usando-se os compostos e as composições desta invenção. Esta invenção também refere-se a métodos de preparação dos compostos desta invenção.Invention Patent: <B> "CASPASE INHIBITORS" <D>. The present invention relates to new classes of compounds that are caspase inhibitors, in particular interleukin-1beta converting enzyme ("ICE") inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for the inhibition of caspase activity and therefore can be advantageously used as agents against diseases mediated by interleukin-1 ("IL-1"), apoptosis, interferon inducing factor - <sym> (IGIF), or interferon- <sym> ("IFN- <sym>"), including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN- <sym> production and methods for treating interferon- <sym> -mediated diseases, apoptosis, and interleukin- 1 using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.

BR9909660-9A 1998-03-19 1999-03-19 Caspase inhibitors BR9909660A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7877098P 1998-03-19 1998-03-19
PCT/US1999/005919 WO1999047545A2 (en) 1998-03-19 1999-03-19 Inhibitors of caspases

Publications (1)

Publication Number Publication Date
BR9909660A true BR9909660A (en) 2000-11-21

Family

ID=22146109

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9909660-9A BR9909660A (en) 1998-03-19 1999-03-19 Caspase inhibitors
BRPI9909660A BRPI9909660B8 (en) 1998-03-19 1999-03-19 caspase inhibitor compounds, pharmaceutical composition and use of said compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9909660A BRPI9909660B8 (en) 1998-03-19 1999-03-19 caspase inhibitor compounds, pharmaceutical composition and use of said compounds

Country Status (34)

Country Link
US (3) US6531474B1 (en)
EP (6) EP2261232A3 (en)
JP (3) JP4594520B2 (en)
KR (2) KR100928878B1 (en)
CN (1) CN1321129C (en)
AP (1) AP2000001919A0 (en)
AR (1) AR019011A1 (en)
AT (1) ATE410439T1 (en)
AU (1) AU769033B2 (en)
BG (1) BG104863A (en)
BR (2) BR9909660A (en)
CA (1) CA2324226C (en)
CZ (1) CZ302281B6 (en)
DE (1) DE69939689D1 (en)
DK (1) DK1064298T3 (en)
ES (1) ES2315010T3 (en)
GE (1) GEP20043163B (en)
HK (1) HK1035733A1 (en)
HU (1) HU227920B1 (en)
ID (1) ID27002A (en)
IL (3) IL138469A0 (en)
IS (1) IS5622A (en)
NO (1) NO331829B1 (en)
NZ (2) NZ506963A (en)
PL (1) PL204619B1 (en)
PT (1) PT1064298E (en)
RU (1) RU2274642C2 (en)
SI (1) SI1064298T1 (en)
SK (1) SK286736B6 (en)
TR (1) TR200103406T2 (en)
TW (1) TWI243828B (en)
UA (2) UA74133C2 (en)
WO (1) WO1999047545A2 (en)
ZA (1) ZA200004652B (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1064298E (en) * 1998-03-19 2009-01-02 Vertex Pharma Inhibitors of caspases
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US7326542B2 (en) 1998-12-02 2008-02-05 Princeton University Compositions and methods for regulating bacterial pathogenesis
US6720415B2 (en) 1998-12-02 2004-04-13 Princeton University Compositions and methods for regulating bacterial pathogenesis
CA2386411A1 (en) * 1999-10-13 2001-04-19 Merck Frosst Canada & Co. Nicotinyl aspartyl ketones as inhibitors of caspase-3
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
JP2003532698A (en) 2000-05-10 2003-11-05 プリンストン ユニバーシティ Compounds and methods for regulating bacterial growth and pathogenesis
PE20011350A1 (en) 2000-05-19 2002-01-15 Vertex Pharma PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE)
PE20020500A1 (en) * 2000-09-13 2002-06-25 Vertex Pharma DERIVATIVES OF PIPERIDINE, TETRAHYDROQUINOLINE, TETRAHYDROISOQUINOLINE AS DANDRUFF INHIBITORS
WO2002070544A2 (en) * 2001-03-02 2002-09-12 Idun Pharmaceuticals, Inc. Methods, compositions and kits for preserving antigenicity
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
WO2003068242A1 (en) * 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
FR2839309B1 (en) 2002-05-03 2004-07-23 Aventis Pharma Sa NOVEL DERIVATIVES OF HEXAHYDRO-PYRIDAZINE-3- CARBOXYLIC ACID, CHEMOTHEKS CONTAINING THEM, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MXPA05002514A (en) 2002-09-06 2005-05-27 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody.
ATE380185T1 (en) 2002-10-23 2007-12-15 Glenmark Pharmaceuticals Ltd TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGY DISEASES: METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2846969A1 (en) * 2002-11-08 2004-05-14 Salles Jean Pierre New modified active agent derivatives with improved bioavailability comprising parent drug, e.g. anticancer agent, plus fluorinated hydrocarbon chain and recognition or hydrophilizing moiety
AU2003295041A1 (en) * 2002-11-20 2004-06-18 L'oreal Composition for hair care or eyelashes containing a pyrazol-carboxamide, its use for stimulating hair and eyelash growth and/or for preventing loss thereof
FR2847160A1 (en) * 2002-11-20 2004-05-21 Oreal Use of pyrazole-4-carboxamides as 15-hydroxy prostaglandin dehydrogenase inhibitors, e.g. for inducing or stimulating hair growth or inhibiting hair loss
EP1620429B1 (en) 2003-04-11 2009-04-01 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
CA2547670A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ice inhibitors
ES2320643T3 (en) * 2003-12-12 2009-05-27 Dr. Straetmans Chemische Produkte Gmbh COMPOSITIONS WITH ANISIC ACID AND GLYCERIDES.
AU2011226946B2 (en) * 2004-02-27 2012-05-03 Vertex Pharmaceuticals Incoporated Caspase Inhibitors and Uses Thereof
CN1942466B (en) * 2004-02-27 2011-02-23 沃泰克斯药物股份有限公司 Caspase inhibitors and uses thereof
EP2270004A1 (en) 2004-02-27 2011-01-05 Vertex Pharmceuticals Incorporated Caspase inhibitors and uses thereof
JP4898658B2 (en) 2004-03-12 2012-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド Methods and intermediates for the preparation of aspartate acetal caspase inhibitors
CA2565188C (en) * 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CN1980658A (en) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 Treatment of diseases using ICE inhibitors
WO2006017295A2 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
US7709524B2 (en) * 2004-09-17 2010-05-04 Biomas Ltd. Use of tellurium compounds for inhibition of interleukin-converting enzyme
BRPI0516341A (en) 2004-10-13 2008-09-02 Glenmark Pharmaceuticals Sa method for preparing n- (3,5-dichloropyrid-4-yl) -4-difluoromethoxy-8-methanes ulfonamido-dibenzo [b, d] furan-1-carboxamide intermediates, method for preparing n-intermediate compounds - (3,5-dichloropyrid-4-yl) -4-difluoromethoxy-8-methanes sulfonamido-dibenzo [b, d] furan-1-carboxamide, n- (3,5-dichloropyrid-4-yl) -4- difluoromethoxy-8-methanes ulfonamido-dibenzene [b, d] furan-1-carboxamide, method for the synthesis of n- (3,5-dichloropyrid-4-yl) -4-difluoromethoxy-8-methanes ulfonamido-dibenzo [b , d] furan-1-carboxamide and its n- (3,5-dichloropyrid-4-yl) -4-difluoromethoxy-8-methanes ulfonamido-dibenzo [b, d] furan-1-carboxamide sodium salt
PL1831227T3 (en) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
SI1831227T1 (en) 2004-12-17 2013-09-30 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
JP4673068B2 (en) * 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Th1 type allergic disease treatment composition
DE102005017116A1 (en) 2005-04-13 2006-10-26 Novartis Ag Inhibitors of Inhibitors of Apoptosis Proteins (IAP)
NZ566022A (en) 2005-07-28 2011-04-29 Vertex Pharma Caspase inhibitor prodrugs
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
EP2043672A4 (en) * 2006-07-07 2009-10-21 Univ Leland Stanford Junior Selective caspase inhibitors
JP2010510224A (en) * 2006-11-17 2010-04-02 アボット・ラボラトリーズ Aminopyrrolidines as chemokine receptor antagonists
US8618663B2 (en) 2007-09-20 2013-12-31 International Business Machines Corporation Patternable dielectric film structure with improved lithography and method of fabricating same
US8084862B2 (en) * 2007-09-20 2011-12-27 International Business Machines Corporation Interconnect structures with patternable low-k dielectrics and method of fabricating same
US7709370B2 (en) 2007-09-20 2010-05-04 International Business Machines Corporation Spin-on antireflective coating for integration of patternable dielectric materials and interconnect structures
WO2009124265A1 (en) * 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
GB2475799A (en) * 2008-05-27 2011-06-01 Imp Innovations Ltd Hypoxia inducing factor (hif) stabilising glasses
US20110152343A1 (en) * 2009-12-22 2011-06-23 Functional Genetics, Inc. Protease inhibitors and broad-spectrum antiviral
GB201001070D0 (en) 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
GB201011411D0 (en) 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
PL2766346T3 (en) 2011-10-14 2017-09-29 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2699226T3 (en) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as inhibitors of factor XIa
CN103987696B (en) 2011-10-14 2016-12-21 百时美施贵宝公司 Substituted tetrahydro isoquinoline compound as factor XI, plasma thromboplastin antecedent A inhibitor
SG11201501036RA (en) 2012-08-23 2015-03-30 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
SI2906551T1 (en) 2012-10-12 2018-05-31 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
HUE040226T2 (en) 2014-01-31 2019-02-28 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6966996B2 (en) * 2015-09-17 2021-11-17 シティ・オブ・ホープCity of Hope PCNA inhibitor
WO2018016547A1 (en) * 2016-07-22 2018-01-25 キッセイ薬品工業株式会社 Pyrrolidine derivative
CA3047836C (en) 2016-12-23 2024-02-06 Andrea Leblanc Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP4251140A1 (en) * 2020-11-25 2023-10-04 Lysosomal and Rare Disorders Research and Treatment Center, Inc. Inhibition of caspase pathway as a treatment for lysosomal storage disorders

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2973111A (en) * 1958-02-11 1961-02-28 Dempster Brothers Inc Compaction bodies
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US4465679A (en) 1983-01-31 1984-08-14 Usv Pharmaceutical Corporation 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
IL72523A (en) 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5158936A (en) 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5008245A (en) 1988-10-27 1991-04-16 University Of Kentucky Research Foundation Novel peptidyl carbamate inhibitors of the enzyme elastase
ZA905737B (en) 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
EP0503561B1 (en) 1991-03-15 1998-10-28 Hoechst Aktiengesellschaft Method for the diastereoselective reductive pinacol coupling of homochiral alpha aminoaldehydes
EP0519748B1 (en) * 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
JP3190431B2 (en) 1991-07-01 2001-07-23 三菱化学株式会社 Ketone derivatives
US6348570B1 (en) 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
US5278061A (en) 1991-08-16 1994-01-11 Merck & Co., Inc. Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme
EP0533226A3 (en) 1991-08-16 1993-08-18 Merck & Co. Inc. Novel chromophore containing compounds
EP0533350B1 (en) 1991-08-16 1999-05-26 Merck & Co. Inc. DNA encoding precursor interleukin 1B converting enzyme
HU220098B (en) 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 beta protease and interleukin-1 beta protease inhibitors
EP0541946B1 (en) 1991-10-07 1996-07-17 Hoechst Aktiengesellschaft Process for diastereo selective reductive pinacol-coupling of homochiral alpha-aminoaldehydes
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU1339092A (en) 1991-12-13 1993-07-19 Corvas International, Inc. Reagents for automated synthesis of peptide analogs
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
DE69320176T2 (en) 1992-02-21 1999-04-08 Merck & Co Inc PEPTIDYL DERIVATIVES AND INHIBITORS OF THE INTERLEUKIN-1-G (B)-CONVERTING ENZYME
JPH08500242A (en) 1992-06-24 1996-01-16 メルク エンド カンパニー インコーポレーテッド DNA encoding interleukin-1β precursor convertase
JP2602181B2 (en) 1992-07-31 1997-04-23 ファイザー・インク． Peptidyl 4-amino-2,2-difluoro-3-oxo-1,6-hexanedioic acid derivative as anti-inflammatory agent
CA2109646C (en) 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents.
TW494094B (en) 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US5411985A (en) 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (en) * 1993-06-03 1995-04-04 Sterling Winthrop Inc Interleukin-1 beta transfer enzyme inhibitor
DE69413167T2 (en) 1993-06-04 1999-05-06 Vertex Pharma Peptide-phosphinyloxymethyl ketones as inhibitors of interleukin-1 beta-converting enzymes
EP0711174A4 (en) 1993-06-24 1997-11-12 Gen Hospital Corp Programmed cell death genes and proteins
WO1995005192A1 (en) 1993-08-13 1995-02-23 Merck & Co., Inc. SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
ATE163639T1 (en) * 1993-11-11 1998-03-15 Basf Ag P-HYDROXYANILINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING HARMFUL FUNGALS OR PESTS
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
HU224731B1 (en) 1994-03-31 2006-01-30 Vertex Pharma Pyrimidinyl derivatives as interleukin inhibitors and pharmaceutical compositions containing them
AU705321B2 (en) 1994-04-29 1999-05-20 Vertex Pharmaceuticals Incorporated Halomethyl amides as IL-1beta protease inhibitors
US5492824A (en) 1994-05-12 1996-02-20 Basf Ag Ice and ice-like compositions and methods of making same
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6057119A (en) 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
JPH09165360A (en) * 1995-03-31 1997-06-24 Takeda Chem Ind Ltd Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
WO1997008174A1 (en) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
EP0851760A4 (en) 1995-08-31 1998-11-25 Smithkline Beecham Corp Interleukin converting enzyme and apoptosis
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6136834A (en) * 1995-12-27 2000-10-24 Ono Pharmaceutical Co., Ltd. Tetrazole compounds and pharmaceutical agents containing such derivative
WO1998001133A1 (en) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
WO1998004539A1 (en) 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Oxygenic heterocyclic derivatives
CA2265853C (en) 1996-09-12 2010-08-03 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1.beta.-converting enzyme (ice)/ced-3 family inhibitors
AU739496B2 (en) 1996-09-12 2001-10-11 Idun Pharmaceuticals, Incorporated Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
JP3492703B2 (en) * 1996-09-12 2004-02-03 アイドゥン ファーマシューティカルズ，インコーポレイテッド C-terminally modified (N-substituted) -2-indolyl dipeptides as inhibitors of the ICE / ced-3 family of cysteine proteases
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
HUP9700816A3 (en) 1997-04-28 1999-06-28 Gyogyszerkutato Intezet 3(r)-3-amino-4-carboxy-butiraldehyde derivatives inhibiting release of interleukin-1-beta
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CA2307844C (en) * 1997-10-31 2006-08-08 Kimberly-Clark Worldwide, Inc. Creped nonwoven materials and liner
PT1064298E (en) * 1998-03-19 2009-01-02 Vertex Pharma Inhibitors of caspases
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
PE20011350A1 (en) 2000-05-19 2002-01-15 Vertex Pharma PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE)
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
EP2270004A1 (en) * 2004-02-27 2011-01-05 Vertex Pharmceuticals Incorporated Caspase inhibitors and uses thereof
CN1980658A (en) * 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 Treatment of diseases using ICE inhibitors

Also Published As

Publication number Publication date
AU3098699A (en) 1999-10-11
BRPI9909660B1 (en) 2018-09-18
IL138469A0 (en) 2001-10-31
HU227920B1 (en) 2012-06-28
ID27002A (en) 2001-02-22
UA96113C2 (en) 2011-10-10
KR20010042038A (en) 2001-05-25
CZ20003409A3 (en) 2001-01-17
CN1321129C (en) 2007-06-13
PL343611A1 (en) 2001-08-27
CA2324226C (en) 2012-06-05
SK13822000A3 (en) 2001-04-09
TWI243828B (en) 2005-11-21
BG104863A (en) 2001-04-30
HUP0103575A2 (en) 2002-02-28
EP2011800A2 (en) 2009-01-07
EP2261235A3 (en) 2011-04-20
CA2324226A1 (en) 1999-09-23
NZ506963A (en) 2003-10-31
JP2010241822A (en) 2010-10-28
US8691848B2 (en) 2014-04-08
EP2261234A2 (en) 2010-12-15
CZ302281B6 (en) 2011-01-26
KR20080020703A (en) 2008-03-05
EP2011800A3 (en) 2009-06-24
IS5622A (en) 2000-09-08
EP1064298B1 (en) 2008-10-08
JP4594520B2 (en) 2010-12-08
DE69939689D1 (en) 2008-11-20
NO331829B1 (en) 2012-04-16
EP1064298A2 (en) 2001-01-03
DK1064298T3 (en) 2009-01-19
JP2002506878A (en) 2002-03-05
TR200103406T2 (en) 2002-06-21
HUP0103575A3 (en) 2002-10-28
EP2261235A2 (en) 2010-12-15
US6531474B1 (en) 2003-03-11
SK286736B6 (en) 2009-04-06
JP2006206600A (en) 2006-08-10
WO1999047545A2 (en) 1999-09-23
EP2261233A2 (en) 2010-12-15
ES2315010T3 (en) 2009-03-16
GEP20043163B (en) 2004-01-26
KR100898094B1 (en) 2009-05-18
NO20004546D0 (en) 2000-09-12
CN1323314A (en) 2001-11-21
NZ528282A (en) 2005-05-27
EP2261232A3 (en) 2011-04-20
PL204619B1 (en) 2010-01-29
US20030232986A1 (en) 2003-12-18
AU769033B2 (en) 2004-01-15
SI1064298T1 (en) 2009-02-28
KR100928878B1 (en) 2009-11-30
EP2261232A2 (en) 2010-12-15
AR019011A1 (en) 2001-12-26
BRPI9909660B8 (en) 2021-05-25
RU2274642C2 (en) 2006-04-20
HK1035733A1 (en) 2001-12-07
AP2000001919A0 (en) 2000-09-30
UA74133C2 (en) 2005-11-15
ATE410439T1 (en) 2008-10-15
EP2261234A3 (en) 2011-04-20
NO20004546L (en) 2000-11-09
IL138469A (en) 2010-11-30
EP2261233A3 (en) 2011-04-20
IL206621A0 (en) 2010-12-30
US7358273B2 (en) 2008-04-15
WO1999047545A3 (en) 1999-11-25
ZA200004652B (en) 2002-04-24
US20090048226A1 (en) 2009-02-19
PT1064298E (en) 2009-01-02

Similar Documents

Publication Publication Date Title
BR9909660A (en) Caspase inhibitors
DE69736984D1 (en) INHIBITORS OF INTERLEUKIN-1-BETA CONVERTING ENZYME
BRPI9612258B8 (en) interleukin-1beta converting enzyme inhibitors as well as pharmaceutical composition.
DE69936102D1 (en) USE OF TNF-ALPHA INHIBITORS FOR THE TREATMENT OF NERVE ROOT DAMAGE
BRPI0407993A (en) p38 inhibitors and methods for using them
HK1033828A1 (en) 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
HUP9902254A2 (en) Inhibitors of interleukin-1beta converting enzyme
DE602004014170D1 (en) BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
ATE450269T1 (en) PEPTIDE PYYÄ3-36Ü FOR THE TREATMENT OF METABOLIC DISEASES
DE60120691D1 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF OSTEOPOROSIS AND / OR INFLAMMATORY JOINT DISEASES
DE69732712D1 (en) INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME
YU84102A (en) New dibenzoazulene compounds as tumor necrosis factor inhibitors
ATE311853T1 (en) USE OF CRILLENZYMES TO TREAT PLAQUE
BR9611897A (en) Benzofuran carboxamides and sulfonamides
BR9807622A (en) Self-regulated inflammatory cell apoptosis by gene therapy
ATE309811T1 (en) ANALGESIC FROM SNAKE VENOM
BR0309009A (en) Method for the treatment of mucus hypersecretion
BRPI9917881B8 (en) caspase inhibitor compounds, pharmaceutical composition and use of said compounds
FI982198A (en) IL mutein
MY128938A (en) A herbal composition

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O DEPOSITANTE DEVERA COMPLEMENTAR A TAXA RELATIVA AO EXAME DAS REIVINDICACOES EXCEDENTES.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 19/03/2019